O´Shaughnessey et al.: Analysis of Patients Without an Initial Triple-Negative Breast Cancer Diagnosis in the Phase 3 ASCENT Study of Sacituzumab Govitecan in Metastatic TNBC

Zurück zur Übersicht

16.-21.09.2020 / ESMO 2021

Poster zu Onkologie

Sacituzumab Govitecan Efficacy in Patients with Metastatic Triple-Negative Breast Cancer by HER2 Immunohistochemistry Status: Findings from the Phase 3 ASCENT Study

04.05.2022

Hurvitz et al.: Sacituzumab Govitecan Efficacy in Patients with Metastatic Triple-Negative Breast Cancer by HER2 Immunohistochemistry Status: Findings from the Phase 3 ASCENT Study

03.-05.05.2022 / ESMO BC 2022

Carey et al.: Assessment of Sacituzumab Govitecan in Black Patients From the Phase 3 ASCENT Study in Metastatic Triple‑Negative Breast Cancer

07.-10.12.2021 / ASCO 2021

Cortes et al.: Post-Progression Therapy Outcomes in Patients From the Phase 3 ASCENT Study of Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

07.-10.12.2021 / SABCS 2021

Loibl et al.: Assessment of health-related quality of life by clinical response from the phase 3 ASCENT study in metastatic triple-negative breast cancer (mTNBC)

07.-10.12.2021 / SABCS 2021

Loibl et al.: Health-related quality of life (HRQoL) in the ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC)

16.-21.09.2021 / ESMO 2021

Carey et al.: Assessment of Sacituzumab Govitecan in Patients With Prior Neoadjuvant/Adjuvant Chemotherapy and One Line of Therapy in the Metastatic Setting in the Phase 3 ASCENT Study in Metastatic Triple-Negative Breast Cancer: 2nd-Line Subgroup

04.-08.06.2021 / ASCO 2021

O´Shaughnessey et al.: Assessment of Sacituzumab Govitecan vs Treatment of Physician’s Choice Cohort by Agent in the Phase 3 ASCENT Study of Patients With Metastatic Triple‑Negative Breast Cancer

04.-05.06.2021 / ASCO 2021

Rugo et al.: Impact of UGT1A1 Status on the Safety Profile of Sacituzumab Govitecan in the Phase 3 ASCENT Study in Patients With Metastatic Triple‑Negative Breast Cancer

08.-11.12.2020 / SABCS 2020

Dieras et al.: Subgroup Analysis of Patients With Brain Metastases From the Phase 3 ASCENT Study of Sacituzumab Govitecan Versus Chemotherapy in Metastatic Triple‑Negative Breast Cancer

08.-11.12.2020 / SABCS 2020